The FDA is requiring Eli Lilly to collect additional post-approval safety data for its newly approved oral GLP-1 weight loss pill, Foundayo — including a pregnancy outcomes registry and studies probing potential liver injury and heart risks like heart attack and stroke, per the agency’s approval letter posted Tuesday. The drug was cleared this month via the FDA Commissioner’s National Priority Voucher fast-track program, raising the stakes for real-world safety surveillance.

The move

• FDA told Lilly the current evidence base isn’t sufficient to fully characterize several potential risks for Foundayo (orforglipron), including drug-induced liver injury and heart problems (e.g., heart attack, stroke).

• The agency also wants more data on delayed gastric emptying.

• FDA is requiring new postmarketing work, including a pregnancy outcomes registry and a registry tracking children with obesity who use weight loss drugs.

• FDA also asked Lilly to collect thyroid cancer risk data for at least 15 years (injectable GLP-1s already carry a boxed warning about a rare thyroid cancer risk).

Why it Matters for Care

• Clinicians should expect tighter monitoring and more conservative counseling early in Foundayo uptake, particularly for patients with cardiovascular risk factors or prior liver disease, given FDA’s explicit focus on heart and hepatic signals.

• Pregnancy counseling becomes operational: patients of reproductive potential may be directed toward enrollment in the pregnancy outcomes registry, and practices may need workflows for reporting exposures and outcomes.

• Watch for evolving guidance around GI adverse effects (delayed gastric emptying) that can affect medication timing, peri-procedural planning, and tolerability-driven discontinuation.

Between the Lines

• Fast-track clearance via the Commissioner’s National Priority Voucher can shift uncertainty downstream: faster approval now, heavier postmarket evidence generation later.

• FDA treated Foundayo differently than Novo Nordisk’s recently approved Wegovy pill (semaglutide), likely because semaglutide has been on the market since 2017 and has a deeper safety record, while orforglipron is a newer, non-peptide GLP-1.

• For clinicians and policymakers, this is the GLP-1 era’s core tradeoff: rapid access to high-demand obesity therapies vs. the political and clinical risk of rare but serious adverse events emerging in broader use.

What to Watch

• FDA’s postmarketing study protocols and timelines, including how quickly the pregnancy registry and pediatric obesity registry begin enrolling.

• Any label updates, safety communications, or REMS-like requirements if liver or cardiovascular signals strengthen in real-world data.

• Whether Congress or HHS increases scrutiny of the National Priority Voucher pilot if high-profile safety questions cluster around fast-tracked products.

• Comparative safety readouts between oral GLP-1s (Foundayo vs. Wegovy pill) as utilization expands.

Source: NBC News Health